Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

A Study of Single and Multiple Subcutaneous or Intravenous Doses of ADX-001 in Healthy Adults to Assess Safety, Effects, and Immune Response

2. listopadu 2026 aktualizováno: Adaxion Therapeutics

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Subcutaneous and Intravenous ADX-001 in Healthy Adult Participants

This is a phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of subcutaneous and intravenous ADX-001 in healthy adult participants

Přehled studie

Postavení

Nábor

Podmínky

Detailní popis

ADX-001 is a new investigational medicine being developed to treat inflammatory diseases, such as inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, and certain rheumatic diseases, such as psoriatic arthritis.

The purpose of this study is to evaluate the safety and tolerability of ADX-001 in healthy adult volunteers. The study will also examine how the body processes the medicine, how the medicine affects the immune system, and whether the body develops antibodies against the medicine. The results of this study will help determine appropriate doses and dosing schedules for future studies in patients with inflammatory diseases.

Typ studie

Intervenční

Zápis (Odhadovaný)

88

Fáze

  • Fáze 1

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

    • South Australia
      • Adelaide, South Australia, Austrálie, 5000
        • Nábor
        • CMAX Clinical Research

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let až 55 let (Dospělý)

Přijímá zdravé dobrovolníky

Ano

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Provide informed consent - Be willing and able to sign a consent form after understanding the study and before any study-related procedures are performed.
  • Age - Be a healthy adult male or female aged 18 to 55 years.
  • Body weight and BMI - Have a Body Mass Index (BMI) between 18.0 and 32.0 kg/m². Weigh more than 50 kg and less than 120 kg.
  • For women who can become pregnant - Have a negative pregnancy test before participating.
  • Use highly effective birth control during the study and for 15 months after the last study dose.

Exclusion Criteria:

You cannot participate in this study if any of the following apply to you:

  1. Medical Conditions

    • You have a serious or ongoing health condition affecting the heart, lungs, liver, kidneys, digestive system, hormones, nervous system, immune system, or mental health.
    • You have a history of severe allergic reactions, anaphylaxis, or are allergic to the study drug or its ingredients.
  2. Infections

    • You test positive for HIV, hepatitis B, or hepatitis C.
    • You have tuberculosis (TB), a history of TB, recent close contact with someone who has active TB, or a positive TB screening test.
    • You test positive for COVID-19 before receiving the study drug.
    • You have an active or long-term infection requiring treatment.
    • You have needed antibiotics or other anti-infective treatment within the last month.
    • You were hospitalized or required intravenous (IV) treatment for an infection within the last 3 months.
    • You have a history of certain recurring infections, such as shingles (herpes zoster).
    • You have a fever higher than 37.7°C during screening or within 7 days before dosing.
    • In some cases, minor abnormalities may be accepted if the study doctor considers them not clinically important.

4. Heart and Blood Pressure Problems 5. Previous Medications or Treatments

  • You have previously received medicines that target TNFα or IL-23.

  • You have received other biologic medicines within the last 6 months.

  • You have used medicines that significantly suppress the immune system within the required washout period.

  • You have recently used prescription or over-the-counter medications that could affect study results.

  • You received a live vaccine within the last 12 weeks or any other vaccine within the last 4 weeks.

  • You donated blood, plasma, or platelets too recently before joining the study.

    6. Alcohol or Drug Use. 7. Pregnancy and Reproductive Considerations

  • You are pregnant, breastfeeding, or planning to become pregnant during the study period.

  • You are unwilling to use the required birth control methods.

    8. Participation in Other Research Studies

  • You have recently participated in another clinical trial involving an investigational drug or device.

  • You have previously participated in this study.

    9. Ability to Participate

  • You are unable to understand the study requirements or provide informed consent.

  • You are unable or unwilling to follow study procedures and visit schedules.

    10. Conflict of Interest

  • You are an employee of the study sponsor or investigator, or an immediate family member of one.

    11. Other Safety Concerns

  • The study doctor believes that participating could put your health at risk, prevent you from completing the study, or affect the reliability of the study results.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Dvojnásobek

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: SAD Cohort 1-5

ADX-001 administered as a single dose according to the assigned cohort and route of administration (SC or IV).

ADX-001 administered every 4 weeks (Q4W) for a total of 4 doses according to the assigned cohort and route of administration (SC or IV).

Matching placebo administered by SC injection or IV infusion according to the route and dosing schedule of the assigned cohort.

Experimentální: MAD Cohort 6-9

ADX-001 administered as a single dose according to the assigned cohort and route of administration (SC or IV).

ADX-001 administered every 4 weeks (Q4W) for a total of 4 doses according to the assigned cohort and route of administration (SC or IV).

Matching placebo administered by SC injection or IV infusion according to the route and dosing schedule of the assigned cohort.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Časové okno
Incidence and severity of Treatment Emergent Adverse Events (TEAEs) of single and multiple doses of ADX-001 administered by subcutaneous and intravenous injection
Časové okno: From first dose through Day 365 for participants receiving a single dose and through Day 505 for participants receiving multiple doses.
From first dose through Day 365 for participants receiving a single dose and through Day 505 for participants receiving multiple doses.

Sekundární výstupní opatření

Měření výsledku
Časové okno
PK Parameters peak concentration (Cmax) - SAD
Časové okno: Pre-dose on Day 1 through Day 365
Pre-dose on Day 1 through Day 365
PK Parameters peak concentration (Cmax) - MAD
Časové okno: Pre-dose on Day 1 through Day 87
Pre-dose on Day 1 through Day 87
Area under the concentration-time curve (AUC0-t) - SAD
Časové okno: Pre-dose on Day 1 through Day 365
Pre-dose on Day 1 through Day 365
Area under the concentration-time curve (AUC0-t) - MAD
Časové okno: Pre-dose on Day 1 through Day 87
Pre-dose on Day 1 through Day 87
Terminal elimination half-life (t1/2) - SAD
Časové okno: Pre-dose on Day 1 through Day 365
Pre-dose on Day 1 through Day 365
Terminal elimination half-life (t1/2) - MAD
Časové okno: Pre-dose on Day 1 through Day 87
Pre-dose on Day 1 through Day 87
Clearance (CL) - SAD
Časové okno: Pre-dose on Day 1 through Day 365
Pre-dose on Day 1 through Day 365
Clearance (CL) - MAD
Časové okno: Pre-dose on Day 1 through Day 87
Pre-dose on Day 1 through Day 87
Volume of distribution (Vz) - SAD
Časové okno: Pre-dose on Day 1 through Day 365
Pre-dose on Day 1 through Day 365
Volume of distribution (Vz) - MAD
Časové okno: Pre-dose on Day 1 through Day 87
Pre-dose on Day 1 through Day 87
Serum concentrations of free CD22L- SAD
Časové okno: Pre-dose on Day 1 through Day 365
Pre-dose on Day 1 through Day 365
Serum concentrations of free CD22L- MAD
Časové okno: Pre-dose on Day 1 through Day 87
Pre-dose on Day 1 through Day 87
Incidence of treatment-emergent anti-drug antibodies (ADA)
Časové okno: From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
Maximum observed serum concentration (Cmax) of ADX-001 by ADA status
Časové okno: From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
Minimum observed serum concentration (Cmin) of ADX-001 by ADA status
Časové okno: From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
Area under the serum concentration-time curve (AUC0-last) of ADX-001 by ADA status
Časové okno: From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
Area under the serum concentration-time curve over the dosing interval (AUCτ) of ADX-001 by ADA status
Časové okno: From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
Clearance (CL) of ADX-001 by ADA status
Časové okno: From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
Terminal elimination half-life (t½) of ADX-001 by ADA status
Časové okno: From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
Incidence of treatment-emergent adverse events by ADA status
Časové okno: From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses
From Day 14 through Day 112 after a single dose, and through 56 days after the final dose following multiple doses

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

20. října 2026

Primární dokončení (Odhadovaný)

29. července 2027

Dokončení studie (Odhadovaný)

14. prosince 2028

Termíny zápisu do studia

První předloženo

2. října 2026

První předloženo, které splnilo kritéria kontroly kvality

11. října 2026

První zveřejněno (Aktuální)

15. října 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

4. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

2. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • ADX-001-CLN-01

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit